Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ELL2P2 is a pseudogene related to the gene elongation factor for RNA polymerase II 2 (ELL2)[1][3][5][7]. Pseudogenes such as ELL2P2 do not encode functional proteins and typically lack biological function, although they are sometimes transcribed[3][7]. There is no evidence that ELL2P2 acts as a therapeutic target, nor is it implicated in disease, biomarker utility, or drug interactions. ELL2P2 should not be confused with ELL2, which encodes a protein component of the super elongation complex (SEC) involved in transcriptional regulation and immunoglobulin synthesis[2][6]. Key point: ELL2P2 is a non-functional pseudogene, not a valid therapeutic or biological target. The entry is considered incorrect as a drug target; if your interest is in transcriptional elongation or related diseases, the correct target would be the parent gene, ELL2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Elongation factor for RNA polymerase II 2 pseudogene 2 (ELL2P2).